Senteon Expands Automated Endpoint Hardening to Microsoft Office The Top HR Trends for 2022
By Lauren Winans Many employers have been actively reevaluating how they approach human resources, especially…
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
International Conference on Alzheimer’s and Parkinson’s Diseases Provides New Insights into the Role of Neuroinflammation…
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a majority-owned…
CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people…
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response…
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of…
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single…
Noema Pharma to Attend and Present at Stifel 2022 CNS Days
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a Swiss-based clinical-stage company targeting…
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life…
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase…
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
– Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than…
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001…
ORYZON to Give Updates on Corporate Progress in March and April
Virtual Bio-Europe Spring 2022 Kempen Life Sciences Conference Asebio Investor Day MADRID, Spain and CAMBRIDGE,…
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable…
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment…
Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Previously reported data demonstrated that roflumilast foam provided statistically significant improvement in disease severity and…
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Aleafia Health Continues to Gain Share in Adult Use Cannabis Market and Drive International Sales Growth
Reached new record market share overall adult use market share of 2.06% in February 2022,…
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data…
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) today announced…